• Je něco špatně v tomto záznamu ?

Effectiveness of Vaccination Against Tick-Borne Encephalitis in the Czech Republic, 2018-2022

J. Kyncl, FJ. Angulo, H. Orlikova, P. Zhang, I. Vlckova, M. Maly, D. Krivohlavkova, LR. Harper, J. Edwards, C. Bender, A. Pilz, W. Erber, H. Madhava, JC. Moïsi

. 2024 ; 24 (9) : 607-613. [pub] 20240701

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019126

Background: Tick-borne encephalitis (TBE) is caused by the tick-borne encephalitis virus (TBEV). TBEV infection can cause symptoms of central nervous system (CNS) inflammation and result in severe consequences including death. TBE is an increasing health threat in the Czech Republic and elsewhere in Europe. In 2020, 23% of 3734 TBE cases reported to the European Centre for Disease Prevention and Control were from the Czech Republic. TBE vaccination is universally recommended in the Czech Republic, but a full analysis of TBE vaccine effectiveness (VE) in the Czech Republic has not been published. Methods: TBE is a notifiable disease in the Czech Republic with mandatory reporting of cases (i.e., laboratory-confirmed TBEV infected patient with symptoms of CNS inflammation) and vaccination history to public health authorities. TBE VE was estimated using the screening method utilizing public health surveillance data from 2018 to 2022 and online household surveys of the general population on TBE vaccine uptake conducted in 2019-2022. Results: In 2018-2022, 3648 TBE cases were reported in the Czech Republic; 98.1% (3105/3166) of TBE cases with known vaccination history were unvaccinated. Among 42,671 persons surveyed from the general population who had known TBE vaccination history, 66.5% were unvaccinated. VE against TBE was 97.6% (95% confidence interval 95.7-98.7). When stratified by age group, VE was 97.1% (88.4-99.3) in 1-15 years of age, 97.9% (95.3-99.0) in 16-59 years of age, and 96.9% (90.5-99.0) in ≥60 years of age. TBE vaccination averted an estimated 1020 TBE cases in the Czech Republic from 2018 to 2022. Conclusions: This first published study with a full analysis of TBE VE in the Czech Republic showed that vaccination was highly effective for the prevention of TBE including in children, an age group with increasing TBE disease burden. Vaccination averted hundreds of TBE cases and hospitalizations despite the relatively low compliance with TBE vaccine recommendations. To prevent additional TBE cases in the Czech Republic, enhanced efforts to increase TBE vaccine uptake are needed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019126
003      
CZ-PrNML
005      
20241024111549.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1089/vbz.2023.0166 $2 doi
035    __
$a (PubMed)38946629
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kyncl, Jan $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Effectiveness of Vaccination Against Tick-Borne Encephalitis in the Czech Republic, 2018-2022 / $c J. Kyncl, FJ. Angulo, H. Orlikova, P. Zhang, I. Vlckova, M. Maly, D. Krivohlavkova, LR. Harper, J. Edwards, C. Bender, A. Pilz, W. Erber, H. Madhava, JC. Moïsi
520    9_
$a Background: Tick-borne encephalitis (TBE) is caused by the tick-borne encephalitis virus (TBEV). TBEV infection can cause symptoms of central nervous system (CNS) inflammation and result in severe consequences including death. TBE is an increasing health threat in the Czech Republic and elsewhere in Europe. In 2020, 23% of 3734 TBE cases reported to the European Centre for Disease Prevention and Control were from the Czech Republic. TBE vaccination is universally recommended in the Czech Republic, but a full analysis of TBE vaccine effectiveness (VE) in the Czech Republic has not been published. Methods: TBE is a notifiable disease in the Czech Republic with mandatory reporting of cases (i.e., laboratory-confirmed TBEV infected patient with symptoms of CNS inflammation) and vaccination history to public health authorities. TBE VE was estimated using the screening method utilizing public health surveillance data from 2018 to 2022 and online household surveys of the general population on TBE vaccine uptake conducted in 2019-2022. Results: In 2018-2022, 3648 TBE cases were reported in the Czech Republic; 98.1% (3105/3166) of TBE cases with known vaccination history were unvaccinated. Among 42,671 persons surveyed from the general population who had known TBE vaccination history, 66.5% were unvaccinated. VE against TBE was 97.6% (95% confidence interval 95.7-98.7). When stratified by age group, VE was 97.1% (88.4-99.3) in 1-15 years of age, 97.9% (95.3-99.0) in 16-59 years of age, and 96.9% (90.5-99.0) in ≥60 years of age. TBE vaccination averted an estimated 1020 TBE cases in the Czech Republic from 2018 to 2022. Conclusions: This first published study with a full analysis of TBE VE in the Czech Republic showed that vaccination was highly effective for the prevention of TBE including in children, an age group with increasing TBE disease burden. Vaccination averted hundreds of TBE cases and hospitalizations despite the relatively low compliance with TBE vaccine recommendations. To prevent additional TBE cases in the Czech Republic, enhanced efforts to increase TBE vaccine uptake are needed.
650    12
$a klíšťová encefalitida $x prevence a kontrola $x epidemiologie $7 D004675
650    _2
$a lidé $7 D006801
650    12
$a vakcinace $7 D014611
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a mladý dospělý $7 D055815
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a předškolní dítě $7 D002675
650    12
$a virové vakcíny $x aplikace a dávkování $7 D014765
650    12
$a viry klíšťové encefalitidy $x imunologie $7 D004669
650    _2
$a senioři $7 D000368
650    _2
$a kojenec $7 D007223
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Angulo, Frederick J $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA
700    1_
$a Orlikova, Hana $u Department of Infectious Diseases Epidemiology, Centre for Epidemiology and Microbiology, National Institute of Public Health, Prague, Czech Republic $u Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zhang, Pingping $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA
700    1_
$a Vlckova, Iva $u Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Maly, Marek $u Department of Biostatistics, National Institute of Public Health, Prague, Czech Republic
700    1_
$a Krivohlavkova, Dagmar $u Pfizer Biopharmaceuticals Group, Prague, Czech Republic
700    1_
$a Harper, Lisa R $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA
700    1_
$a Edwards, Juanita $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA
700    1_
$a Bender, Cody $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA
700    1_
$a Pilz, Andreas $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Vienna, Austria
700    1_
$a Erber, Wilhelm $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Vienna, Austria
700    1_
$a Madhava, Harish $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, London, England
700    1_
$a Moïsi, Jennifer C $u Vaccines, Antivirals, and Evidence Generation, Pfizer Vaccines, Pfizer Inc, Paris, France
773    0_
$w MED00007505 $t Vector borne and zoonotic diseases (Larchmont, N.Y.) $x 1557-7759 $g Roč. 24, č. 9 (2024), s. 607-613
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38946629 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111543 $b ABA008
999    __
$a ok $b bmc $g 2201761 $s 1231099
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 9 $d 607-613 $e 20240701 $i 1557-7759 $m Vector borne and zoonotic diseases (Larchmont, N.Y.) $n Vector Borne Zoonotic Dis $x MED00007505
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace